Cogent Biosciences, Inc. is a biotechnology company that develops precision therapies for genetically defined diseases. The company's lead product candidate, CGT9486, is an oral, small molecule inhibitor of the receptor tyrosine kinase, TRKA, TRKB, and TRKC, which are involved in the growth and spread of cancer cells. Cogent Biosciences was founded in 2015 and is headquartered in Cambridge, Massachusetts.